IS:LUPIN Lupin Limited

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients (APIs), and specialty products in India, the United States, Japan, and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, anti-tuberculosis, and cephalosporin, as well as digital therapeutics platform for doctors and patients. The company is also involved in the provision of biosimilar and over-the-counter products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. It has a licensing, development, and commercialization agreement with Boehringer Ingelheim for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with cancers. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

903.40 INR
As of 01/21/2022

Security Information
Category1:  Global Equity
Category2:  Comon stocks
Category3:  Emerging markets
GICS sector:  Health Care
Index country:  India
Country of incorporation:  India
IPO date:  11/30/1994
Stock exchange:    National Stock Exchange O
Exchange country:   India
Market cap:   410,321,584,128 INR
Current dividend yield:   0.69%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy